You are here: Industry Insights > Emergex

News List

Emergex T-Cell Priming COVID Vax Candidate Holds Potential Against Omicron prnasia
December 01, 2021
Emergex Vaccines Holding Ltd., a company tackling major global infectious disease threats through the development of 100% synthetic T- Cell priming vaccines, confirmed that its Vaccine candidate for SARS-CoV-2...
Emergex Signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz contractpharma
January 07, 2021
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil.
Emergex signs agreement with George Mason University for highly pathogenic RNA virus studies pharmaceutical-business-review
April 24, 2020
Emergex Vaccines Holding, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.
Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases pharmafocusasia
December 03, 2018
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious .....
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine b3cnewswire.
June 04, 2018
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine b3cnewswire
May 23, 2018
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases,
Emergex Vaccines receives grant for universal flu vaccine programme biospectrumasia
May 15, 2018
Emergex’s vaccine combines several proprietary technologies to create an immune response based on ‘reverse engineering’
Emergex wins Innovate UK grant to advance universal flu vaccine pharmatimes
May 15, 2018
The vaccine is 100 percent synthetic and delivers “highly conserved immunogenic peptide fragments from the flu virus to antigen presenting cells in the skin, eliciting a strong and long-lasting T-cell immune response,” it said.